Quviviq (daridorexant) / Shionogi, Simcere, Nxera Pharma, Mochida, Syneos Health, Idorsia  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Quviviq (daridorexant) / Idorsia, Syneos Health, Nxera Pharma, Simcere
NCT03545191 / 2017-004642-20: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Completed
3
930
Europe, Canada, US, RoW
Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd.
Insomnia Disorder
01/20
02/20
NCT03575104 / 2017-004643-20: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Completed
3
924
Europe, Canada, US, RoW
Daridorexant, Placebo
Idorsia Pharmaceuticals Ltd.
Insomnia Disorder
04/20
05/20
NCT03679884 / 2017-004644-38: Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Completed
3
804
Europe, Canada, US, RoW
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd.
Insomnia Disorder
02/21
02/21
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Recruiting
3
200
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
12/25
12/25

Download Options